Pre-made Rozibafusp biosimilar ( Whole mAb Fusion, anti-ICOS therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-499
Anti-ICOS therapeutic antibody (Pre-made Rozibafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rozibafusp alfa (previously AMG 570) is being developed by Amgen and AstraZeneca, for the treatment of systemic lupus erythematosus (SLE) and rheumatoid.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ICOS therapeutic antibody (Pre-made Rozibafusp biosimilar,Whole mAb Fusion)|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6x4t:BE:DF|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Systemic lupus erythematosus|
|Conditions Discontinued||Rheumatoid arthritis|